0
0
New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease | Biogen - Biogen
10/25/23 at 3:32pm
Organization
Biogen.com
43 words
0
Comments
The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
You are the first to view
https://investors.biogen.com/news-releases/news-release-details/new-data-biogens-investigational-antisense-oligonucleotide-aso
Create an account or login to join the discussion